Centanafadine, an investigational medication being developed by Otsuka Pharmaceutical, is a norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI) that has been studied for the treatment of attention-deficit/hyperactivity disorder (ADHD). Recent clinical trials have explored its efficacy and safety in adults with ADHD, and new data are being presented on its use in patients with comorbid anxiety.
In an interview, John Kraus, MD, PhD, discussed the latest findings on centanafadine for ADHD and anxiety. The data suggest that centanafadine may offer a new option for patients who have both conditions, which is common in clinical practice. However, the medication is not yet approved by regulatory agencies, and further research is needed to confirm its benefits and risks.
ADHD often co-occurs with anxiety disorders, complicating treatment. Stimulants, the first-line treatment for ADHD, can sometimes exacerbate anxiety symptoms. Non-stimulant options like atomoxetine and viloxazine are available, but there remains a need for additional effective treatments. Centanafadine's mechanism of action, which targets multiple neurotransmitters, may provide a balanced approach.
The new data, presented at a recent medical conference, are part of ongoing phase 3 trials. While the results are promising, experts caution that they are preliminary and peer-reviewed publications are awaited. Patients should consult their healthcare providers for personalized advice.
